SynthesisPharmacoEconomics2023

A Systematic Review of the Cost-Effectiveness Analyses of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC).

Lara Chayab et al.PubMed ↗Publisher ↗

No numbers read from the abstract.